FDA Medical Review for Tafinlar + Mekinist Approval – Accelerated approval on June 22, 2022, NDA 202806/S-022.

FDA Medical Review for Tafinlar + Mekinist Approval – Accelerated approval on June 22, 2022, NDA 202806/S-022.

Regular price $89.00 USD
Regular price Sale price $89.00 USD
Sale Sold out
Original Request: I would like to receive the FDA medical review for the drug approval of Tafinlar + Mekinist, which received accelerated approval on June 22, 2022. The NDA number corresponding to the drug combination approval is NDA 202806/S-022.
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details